These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 20944654

  • 1. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
    Niessner H, Beck D, Sinnberg T, Lasithiotakis K, Maczey E, Gogel J, Venturelli S, Berger A, Mauthe M, Toulany M, Flaherty K, Schaller M, Schadendorf D, Proikas-Cezanne T, Schittek B, Garbe C, Kulms D, Meier F.
    J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
    [Abstract] [Full Text] [Related]

  • 2. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
    Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, Garbe C, Meier FE.
    J Invest Dermatol; 2008 Aug; 128(8):2013-23. PubMed ID: 18323781
    [Abstract] [Full Text] [Related]

  • 3. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [Abstract] [Full Text] [Related]

  • 4. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 5. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
    Basso AD, Mirza A, Liu G, Long BJ, Bishop WR, Kirschmeier P.
    J Biol Chem; 2005 Sep 02; 280(35):31101-8. PubMed ID: 16006564
    [Abstract] [Full Text] [Related]

  • 6. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL, Guo W, Ji T, Ren T, Yang Y, Li DS, Qu HY, Li X, Tang S, Yan TQ, Tang XD.
    Cancer Biol Ther; 2009 Sep 02; 8(18):1729-36. PubMed ID: 19633425
    [Abstract] [Full Text] [Related]

  • 7. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC, Baxter RD, Hunt KM, Agarwal J, Elmets CA, Athar M, Afaq F.
    Oncotarget; 2015 Sep 29; 6(29):28296-311. PubMed ID: 26299806
    [Abstract] [Full Text] [Related]

  • 8. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 29; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 9. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 29; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 10. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
    Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D.
    Mol Med; 2012 Feb 10; 18(1):19-28. PubMed ID: 21979753
    [Abstract] [Full Text] [Related]

  • 12. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
    López-Fauqued M, Gil R, Grueso J, Hernandez-Losa J, Pujol A, Moliné T, Recio JA.
    Int J Cancer; 2010 Apr 01; 126(7):1549-61. PubMed ID: 19810100
    [Abstract] [Full Text] [Related]

  • 13. The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
    Sun SY, Liu X, Zou W, Yue P, Marcus AI, Khuri FR.
    J Biol Chem; 2007 Jun 29; 282(26):18800-9. PubMed ID: 17493934
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK.
    Mol Cancer Ther; 2008 Apr 29; 7(4):890-6. PubMed ID: 18413802
    [Abstract] [Full Text] [Related]

  • 15. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
    David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S.
    Blood; 2005 Dec 15; 106(13):4322-9. PubMed ID: 16118318
    [Abstract] [Full Text] [Related]

  • 16. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN, Lee SM, Kim JS, Hwang SG.
    Cancer Chemother Pharmacol; 2019 Oct 15; 84(4):809-817. PubMed ID: 31385002
    [Abstract] [Full Text] [Related]

  • 17. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G, Wang M, Hyslop T, Wang Z, Carr BI.
    Int J Cancer; 2010 Dec 15; 127(12):2949-58. PubMed ID: 21351273
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J.
    World J Gastroenterol; 2011 Sep 14; 17(34):3922-32. PubMed ID: 22025881
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y, Selim MA, Burchette J, Beasley GM, McMahon N, Padussis J, Pruitt SK, Ali-Osman F, Tyler DS.
    Mol Cancer Ther; 2010 Jul 14; 9(7):2090-101. PubMed ID: 20571072
    [Abstract] [Full Text] [Related]

  • 20. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK.
    PLoS One; 2012 Jul 14; 7(7):e40439. PubMed ID: 22808163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.